



AMERICAN SOCIETY OF CLINICAL ONCOLOGY

2006 Oncology Demonstration Project* Codes

Section 1: Primary Focus of Visit	
G9050	Work-up, evaluation, or staging at the time of cancer diagnosis or recurrence
G9051	Treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy
G9052	Surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future
G9053	Expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future
G9054	Supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative therapies
G9055	Other, unspecified service not otherwise listed

Section 2: Practice Guideline Adherence	
G9056	Management adheres to guidelines
G9057	Management differs from guidelines as a result of patient enrollment in an institutional review board approved clinical trial
G9058	Management differs from guidelines because the treating physician disagrees with guideline recommendations
G9059	Management differs from guidelines because the patient, after being offered treatment consistent with guidelines, has opted for alternative treatment or management, including no treatment
G9060	Management differs from guidelines for reason(s) associated with patient comorbid illness or performance status not factored into guidelines
G9061	Patient's condition not addressed by available guidelines
G9062	Management differs from guidelines for other reason(s) not listed

Section 3: Current Disease State	
<i>Lung cancer (G9063-G9070)</i>	
G9063	limited to non-small cell lung cancer ; extent of disease initially established as Stage I (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9064	limited to non-small cell lung cancer ; extent of disease initially established as Stage II (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9065	limited to non-small cell lung cancer ; extent of disease initially established as Stage IIIA (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases

*Hematologists/oncologists who bill one code from each of the three sections (primary focus of visit, practice guideline adherence, and current disease state) in conjunction with a level 2-5 E & M established patient office visit will qualify for an additional \$23 Medicare payment under the 2006 Oncology Demonstration Program. There is no requirement that the patient encounter be related to chemotherapy.



AMERICAN SOCIETY OF CLINICAL ONCOLOGY

G9066	limited to non-small cell lung cancer ; Stage IIIB- IV at diagnosis, metastatic, locally recurrent, or progressive
G9067	limited to non-small cell lung cancer ; extent of disease unknown, under evaluation, not yet determined, or not listed
G9068	limited to small cell and combined small cell/non-small cell ; extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases
G9069	small cell lung cancer, limited to small cell and combined small cell/non-small cell ; extensive stage at diagnosis, metastatic, locally recurrent, or progressive
G9070	small cell lung cancer, limited to small cell and combined small cell/non-small cell ; extent of disease unknown, under evaluation, pre-surgical, or not listed
Breast cancer (G9071-G9076)	
G9071	invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage I or Stage IIA-IIB; or T3, N1, M0; and ER and/or PR positive; with no evidence of disease progression, recurrence, or metastases
G9072	invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage I or Stage IIA-IIB; or T3, N1, M0; and ER and PR negative; with no evidence of disease progression, recurrence, or metastases
G9073	invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage IIIA-IIIIB; and not T3, N1, M0; and ER and/or PR positive; with no evidence of disease progression, recurrence, or metastases
G9074	invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage IIIA-IIIIB; and not T3, N1, M0; and ER and PR negative; with no evidence of disease progression, recurrence, or metastases
G9075	invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive
G9076	invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; extent of disease unknown, under evaluation, pre-surgical or not listed
Prostate cancer (G9077-G9083)	
G9077	prostate cancer ; limited to adenocarcinoma as predominant cell type; T1-T2C and Gleason 2-7 and PSA < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases
G9078	prostate cancer ; limited to adenocarcinoma as predominant cell type; T2 or Gleason 8-10 or PSA > 20 at diagnosis with no evidence of disease progression, recurrence, or metastases
G9079	prostate cancer ; limited to adenocarcinoma as predominant cell type; T3B-T4, any N; any T, N1 at diagnosis with no evidence of disease progression, recurrence, or metastases
G9080	prostate cancer ; limited to adenocarcinoma; after initial treatment with rising PSA or failure of PSA decline
G9081	prostate cancer ; limited to adenocarcinoma; non-castrate, incompletely castrate; clinical metastases or M1 at diagnosis
G9082	prostate cancer ; limited to adenocarcinoma; castrate; clinical metastases or M1 at diagnosis
G9083	prostate cancer ; limited to adenocarcinoma; extent of disease unknown, under evaluation or not listed
Colon cancer (G9084-G9089)	
G9084	colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-3, N0, M0 with no evidence of disease progression, recurrence, or metastases
G9085	colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T4, N0, M0 with no

*Hematologists/oncologists who bill one code from each of the three sections (primary focus of visit, practice guideline adherence, and current disease state) in conjunction with a level 2-5 E & M established patient office visit will qualify for an additional \$23 Medicare payment under the 2006 Oncology Demonstration Program. There is no requirement that the patient encounter be related to chemotherapy.



AMERICAN SOCIETY OF CLINICAL ONCOLOGY

	evidence of disease progression, recurrence, or metastases
G9086	colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-4, N1-2, M0 with no evidence of disease progression, recurrence, or metastases
G9087	colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive with current clinical, radiologic, or biochemical evidence of disease
G9088	colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive without current clinical, radiologic, or biochemical evidence of disease
G9089	colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, not yet determined, under evaluation, pre-surgical, or not listed
Rectal cancer (G9090-G9095)	
G9090	rectal cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-2, N0, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9091	rectal cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T3, N0, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9092	rectal cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-3, N1-2, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9093	rectal cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T4, any N, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9094	rectal cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive
G9095	rectal cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, not yet determined, under evaluation, pre-surgical, or not listed
Esophageal cancer (G9096-G9099)	
G9096	esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as T1-T3, N0-N1, or NX (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9097	esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as T4, any N, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9098	esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive
G9099	esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease unknown, not yet determined, under evaluation, pre-surgical, or not listed
Gastric cancer (G9100-G9104)	
G9100	gastric cancer , limited to adenocarcinoma as predominant cell type; post R0 resection (with or without neo-adjuvant therapy) with no evidence of disease progression, recurrence, or metastases
G9101	gastric cancer , limited to adenocarcinoma as predominant cell type; post R1 or R2 resection (with or without neo-adjuvant therapy) with no evidence of disease progression, recurrence, or metastases
G9102	gastric cancer , limited to adenocarcinoma as predominant cell type; clinical or pathologic M0, unresectable with no evidence of disease

*Hematologists/oncologists who bill one code from each of the three sections (primary focus of visit, practice guideline adherence, and current disease state) in conjunction with a level 2-5 E & M established patient office visit will qualify for an additional \$23 Medicare payment under the 2006 Oncology Demonstration Program. There is no requirement that the patient encounter be related to chemotherapy.



AMERICAN SOCIETY OF CLINICAL ONCOLOGY

	progression, or metastases
G9103	gastric cancer , limited to adenocarcinoma as predominant cell type; clinical or pathologic M1 at diagnosis, metastatic, locally recurrent, or progressive
G9104	gastric cancer , limited to adenocarcinoma as predominant cell type; extent of disease unknown, under evaluation, not yet determined, pre-surgical, or not listed
<i>Pancreatic cancer (G9105-G9108)</i>	
G9105	pancreatic cancer , limited to adenocarcinoma as predominant cell type; post R0 resection without evidence of disease progression, recurrence, or metastases
G9106	pancreatic cancer , limited to adenocarcinoma; post R1 or R2 resection with no evidence of disease progression, recurrence, or metastases
G9107	pancreatic cancer , limited to adenocarcinoma; unresectable at diagnosis, M1 at diagnosis, metastatic, locally recurrent, or progressive
G9108	pancreatic cancer , limited to adenocarcinoma; extent of disease unknown, under evaluation, not yet determined, pre-surgical, or not listed
<i>Head and neck cancer (G9109-G9112)</i>	
G9109	head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as T1-T2 and N0, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9110	head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as T3-T4 and/or N1-3, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases
G9111	head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive
G9112	head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, under evaluation, not yet determined, pre-surgical, or not listed
<i>Ovarian cancer (G9113-G9117)</i>	
G9113	ovarian cancer, limited to epithelial cancer ; pathologic Stage IA-B (Grade 1) without evidence of disease progression, recurrence, or metastases
G9114	ovarian cancer, limited to epithelial cancer ; pathologic Stage IA-B (Grade 2-3); or Stage IC (all grades); or Stage II; without evidence of disease progression, recurrence, or metastases
G9115	ovarian cancer, limited to epithelial cancer ; pathologic Stage III-IV; without evidence of progression, recurrence
G9116	ovarian cancer, limited to epithelial cancer ; evidence of disease progression, or recurrence, and/or platinum resistance
G9117	ovarian cancer, limited to epithelial cancer ; extent of disease unknown, under evaluation, incomplete surgical staging, pre-surgical staging, or not listed
<i>Non-Hodgkin's lymphoma (G9118-G9122)</i>	
G9118	Non-Hodgkin's lymphoma, limited to follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma ; Stage I, II at diagnosis, not relapsed, not refractory
G9119	Non-Hodgkin's lymphoma, limited to follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma ; Stage III, IV not relapsed, not refractory
G9120	Non-Hodgkin's lymphoma, transformed from follicular lymphoma to diffuse large B-cell lymphoma

*Hematologists/oncologists who bill one code from each of the three sections (primary focus of visit, practice guideline adherence, and current disease state) in conjunction with a level 2-5 E & M established patient office visit will qualify for an additional \$23 Medicare payment under the 2006 Oncology Demonstration Program. There is no requirement that the patient encounter be related to chemotherapy.



AMERICAN SOCIETY OF CLINICAL ONCOLOGY

G9121	Non-Hodgkin's lymphoma, limited to follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma; relapsed/refractory
G9122	Non-Hodgkin's lymphoma, limited to follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma; diagnostic evaluation, stage not determined, evaluation of possible relapse or non-response to therapy, or not listed
<i>Chronic myelogenous leukemia (G9123-G9127)</i>	
G9123	Chronic Myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic or molecular remission
G9124	Chronic Myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular remission
G9125	Chronic Myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; blast phase not in hematologic, cytogenetic, or molecular remission
G9126	Chronic Myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; in hematologic, cytogenetic, or molecular remission
G9127	Chronic Myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; extent of disease unknown, under evaluation, not listed
<i>Multiple myeloma (G9128 -G9130)</i>	
G9128	Limited to multiple myeloma , systemic disease; smoldering, Stage 1
G9129	Limited to multiple myeloma , systemic disease; Stage II or higher
G9130	Limited to multiple myeloma , systemic disease; extent of disease unknown, under evaluation, or not listed

*Hematologists/oncologists who bill one code from each of the three sections (primary focus of visit, practice guideline adherence, and current disease state) in conjunction with a level 2-5 E & M established patient office visit will qualify for an additional \$23 Medicare payment under the 2006 Oncology Demonstration Program. There is no requirement that the patient encounter be related to chemotherapy.